Delivery Order SPE2DR25D2014-SPE2DR26FZ83Z
- Not listed
- The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,117.68 on September 26, 2025, for RESTASIS 0.05% Eye Emulsion (60 count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $18,550.26 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60 count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,705.40 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% eye emulsion (30 single-use containers) on November 12, 2025, with completion scheduled for November 13, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a small-value pharmaceutical transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a $10,783.83 firm fixed-price delivery order for Restasis 0.05% Eye Emulsion (60 units), with an ultimate completion date of December 5, 2025. This is a competitively awarded, non-set-aside contract with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RESTASIS 0.05% Eye Emulsion in 60-count units. This is a competitively awarded, firm fixed-price delivery order valued at $1,862.70 with no set-aside designation, with an ultimate completion date of July 23, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,561.92 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,178.96 to AmerisourceBergen Drug Corp for the supply of RESTASIS 0.05% Eye Emulsion (30 units) on December 14, 2025, with completion scheduled for December 15, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies...
- The Defense Logistics Agency awarded a delivery order valued at $3,916.15 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ83ZDelivery Order
The Defense Logistics Agency (DLA) awarded a $2,302.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on December 1, 2025, with an ultimate completion date of December 2, 2025. This is a non-set-aside, competitively awarded contract with performance in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical and medical supply needs through open competition, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This particular order for RESTASIS, an ophthalmic emulsion used to treat dry eye disease, exemplifies the company's role in supplying specialized pharmaceutical products to support military personnel and beneficiary healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 11/30/25 |